ArticleThe veterinary quarterly2026
Prognostic interaction between clinical stage and left atrial remodeling in dogs with myxomatous mitral valve disease.
Article in The veterinary quarterly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxomatous mitral valve disease (MMVD) is leading cause of acquired heart failure in small-breed dogs. Although the American College of Veterinary Internal Medicine (ACVIM) staging is widely used in practice, how each stage and the degree of cardiac remodeling affect survival has not been clearly defined. We aimed to determine whether severe remodeling in dogs with preclinical (stage B2) disease is associated with survival differences compared with dogs with congestive heart failure (CHF; stage C) and less severe remodeling. This retrospective study analyzed 270 dogs with MMVD, stratified by the left atrium-to-aortic root ratio as having mild (<1.9), moderate (1.9-2.2), and severe (≥2.2) left atrial enlargement. Survival for dogs with stage B2 disease with severe LA enlargement did not differ significantly from dogs with stage C disease with mild-to-moderate enlargement. However, within the subgroup with severe LA enlargement, dogs that developed CHF had significantly shorter survival than those that remained in stage B2 (360 vs. 654 days;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.